Pan et al. revealed that methyltransferase-like 3 (METTL3) accelerates miR-221-3p maturation and enhances miR-221-3p expression by increasing m6A modification of pri-miR-221-3p and promotes the drug resistance of BC cells to Adriamycin via the METTL3/miR-221-3p/HIPK2/Che-1 axis [61]. This evidence concerns the gene METTL3 and breast cancer.